Evofem Biosciences Inc

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Jan. 19, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced strong preliminary results for the fourth quarter of 2021, including record growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate). Achieved preliminary net product sales of $3.5 million in Q4, more than double Q3 net product sales.

Evofem Biosciences Announces Record Net Sales and Phexxi Prescriptions in Q4 2021

EVFM received what I believe to be incredibly important news last week.

Evofem: ACA Coverage Of Phexxi Is A Game Changer

Today, investors in women's health company Evofem Biosciences and EVFM stock are dancing, following revised birth control regulations. The post EVFM Stock Heats Up Following ‘Huge Win.

EVFM Stock Heats Up Following ‘Huge Win.' 7 Things to Know.

Evofem Biosciences Inc (NASDAQ: EVFM) shares are trading higher after the Health Resources and Services Administration (HRSA) and the U.S. Department of Labor issued updated guidance related to contraceptive access.  The new guidance specifies that most insurers and pharmacy benefit managers (PBMs) must provide coverage, with no out-of-pocket costs to women, for FDA-approved contraceptive products, like Phexxi, prescribed by healthcare providers.

Why Are Evofem Biosciences Shares Rising On Wednesday?

SAN DIEGO, Jan. 12, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today commended the Health Resources and Services Administration (HRSA) and the U.S. Department of Labor on their separately-issued updated guidance related to contraceptive access.  The new guidance specifies that most insurers and pharmacy benefit managers (PBMs) must provide coverage, with no out-of-pocket costs to women, for U.S. Food and Drug Administration (FDA)-approved contraceptive products, like Phexxi® (lactic acid, citric acid and potassium bitartrate), prescribed by healthcare providers.

Phexxi Access to Expand under New Government Guidance Stating Insurers Must Cover FDA-approved Contraceptives with No Out-of-Pocket Costs to Women

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the Company will present and host one-on-one meetings at the H.C. Wainwright BioConnect Virtual Conference being held from January 10 – 13, 2022.

Evofem Biosciences to Present at H.C. Wainwright BioConnect Conference

Evofem Biosciences Inc (NASDAQ: EVFM) has collaborated with Orion Biotechnology Canada Ltd to evaluate the compatibility and stability of Orion's OB-002 in Evofem's Phexxi vaginal gel to develop a Multipurpose Prevention Technology (MPT) product candidate for indications including the prevention of HIV in women. This collaboration will focus on determining the compatibility and stability of OB-002 in Phexxi and is expected to yield results in Q3 2022.

Evofem, Orion Biotech Join Forces To Develop Multipurpose Product, Including HIV Prevention

SAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) and Orion Biotechnology Canada Ltd. today announced that they have entered into a collaboration agreement to evaluate the compatibility and stability of Orion's novel CCR5 antagonist, OB-002, in Evofem's Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel with the goal of developing a Multipurpose Prevention Technology (MPT) product candidate for indications including the prevention of HIV in women.

Evofem Biosciences and Orion Biotechnology Launch Collaboration to Develop MPT Product Candidate to Include HIV Prevention

The stock price of Evofem Biosciences Inc (NASDAQ: EVFM) increased by over 6% during intraday trading today. This is why it happened.

Evofem Biosciences Stock (EVFM): Why The Price Increased Today

SAN DIEGO, Dec. 9, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced bullish expectations for prescription and net revenue growth in the fourth quarter of 2021. Total monthly prescriptions (TRx) of Phexxi® (lactic acid, citric acid and potassium bitartrate) are on track to surpass 30,000 in the fourth quarter of 2021, representing approximately 70% growth from third quarter TRx levels.

Evofem Biosciences Expects Record High Phexxi Prescriptions and Strong Net Revenue Growth in Fourth Quarter 2021

SAN DIEGO, Dec. 8, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that it intends to adjourn, without conducting any business, its 2021 special meeting of stockholders (the "Special Meeting") scheduled to occur at 8:00 a.m. PST on December 8, 2021, and reconvene at 8:00 a.m.

Evofem Biosciences to Adjourn Special Meeting of Stockholders on December 8, 2021

SAN DIEGO, Nov. 30, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today reported a successful Type C meeting with the U.S. Food and Drug Administration in which agreement was reached on the preliminary submission strategy for EVO100 for two investigational indications: the prevention of urogenital chlamydia in women and the prevention of urogenital gonorrhea in women.  There are currently no FDA-approved prescription products to prevent either of these sexually transmitted infections (STIs).

Evofem Biosciences Announces Successful Type C Meeting with FDA for STI Prevention Product Candidate

SAN DIEGO, Nov. 22, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that it has successfully extended the cumulative net sales covenant timing of its April 2020 Securities Purchase and Security Agreement to June 30, 2023. "We appreciate that these healthcare investors see the potential for long term growth.

Evofem Biosciences Successfully Extends Cumulative Net Sales Covenant Timing to June 30, 2023

SAN DIEGO, Nov. 19, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will participate in a fireside chat and host one-on-one meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held from November 29 – December 2, 2021. The Company's pre-recorded fireside chat will be available for on demand listening beginning at 10:00am ET (7:00am PT) on Monday, November 22, 2021 for 90 days through the Piper Sandler conference site and at https://evofem.investorroom.com/Piper2021.

Evofem Biosciences to Participate in Piper Sandler 33rd Annual Healthcare Conference

Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q3 2021 Results - Earnings Call Transcript

SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and nine-month periods ended September 30, 2021. "We are extremely excited by the initial results of our celebrity DTC campaign, which is driving an increase in awareness of Phexxi among our target audience and substantial growth in prescriptions filled," said Saundra Pelletier, Evofem's Chief Executive Officer.

Evofem Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 10, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that it has submitted the registration for its hormone-free contraceptive vaginal gel to the Mexican Regulatory Agency COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios). "This regulatory submission is the first step toward expanding access to our non-hormonal contraceptive vaginal gel to women outside the United States," said Saundra Pelletier, CEO of Evofem Biosciences.

Evofem Biosciences Announces Regulatory Submission in Mexico for Its Hormone-Free Contraceptive

SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will participate in the Stifel 2021 Virtual Healthcare Conference as follows: Date Tuesday, November 16, 2021 Time 1:20 p.m. ET Format Fireside Chat Room Track 2 Webcast (live and replay) https://wsw.com/webcast/stifel58/evfm/2096280 The webcast will be archived in the Events and Presentations section of the Company's website at https://evofem.investorroom.com/Stifel2021.

Evofem Biosciences to Participate in Stifel 2021 Virtual Healthcare Conference

SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the third quarter ended September 30, 2021 on Monday, November 15, 2021 at 4:30 p.m. ET (1:30 p.m.

Evofem Biosciences to Report Third Quarter 2021 Results and Provide Corporate Update on Monday, November 15, 2021

SAN DIEGO, Oct. 20, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced significant initial results of "House Rules," its national direct-to-consumer (DTC) campaign with celebrity spokeswoman Annie Murphy, aimed at broadening awareness and driving uptake of its hormone-free contraceptive,  Phexxi®  (lactic acid, citric acid and potassium bitartrate) vaginal gel. "Early metrics powerfully demonstrate that our "House Rules" campaign is effectively reaching our target audience, especially women who are beyond hormones," said Saundra Pelletier, Chief Executive Officer of Evofem.

"House Rules" Delivers Strong Initial Results and Drives Phexxi Growth

SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that it has entered into a definitive agreement with Keystone Capital Partners ("Keystone Capital") providing for the issuance and sale of an aggregate of 10,000 shares of Series B Convertible Stock in a registered direct offering for a purchase price of $1,000.00 per share. The aggregate gross proceeds from this offering are expected to be an aggregate of approximately $10.0 million, before deducting estimated offering expenses payable by Evofem, and will close in two equal tranches with the second closing to occur on or about the 10th trading day following the initial closing.

Evofem Biosciences Announces $10 Million Registered Direct Offering of Series B Preferred Stock

Arbutus Biopharma

Aditxt Inc

Adverum Biotechnologies

Ameri Holdings

Are these 10 penny stocks on your watch list this week? The post Best Penny Stocks To Buy This Week?

Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts

SAN DIEGO, Oct. 8, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today commented on a letter from leaders in the House of Representatives to senior Biden Administration officials calling for action to ensure coverage for the full range of contraceptives under the Affordable Care Act (ACA). "I want to take a moment to praise our leaders in Washington who are working to make sure women have broad access to contraceptives, including new products like Phexxi that have been approved by the FDA since the ACA's passage," said Saundra Pelletier, Chief Executive Officer of Evofem.

Evofem Biosciences Commends House of Representatives Leaders for Action to Ensure Coverage for the Full Range of Contraceptives Under ACA

SAN DIEGO, Sept. 30, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will present and host one-on-one meetings at the 14th annual LD Micro Main Event being held in Los Angeles on October 12-14, 2021.

Evofem Biosciences to Present at LD Micro Investor Conference on October 12, 2021

SAN DIEGO, Sept. 27, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that a manuscript on the variability of contraceptive clinical trial design and its impact on efficacy outcomes has been published in the peer-reviewed journal Advances in Therapy.

News for Evofem Biosciences Inc Stock (EVFM)